WO2001005434A3 - Hyaluronic acid-protein conjugates - Google Patents

Hyaluronic acid-protein conjugates Download PDF

Info

Publication number
WO2001005434A3
WO2001005434A3 PCT/US2000/019803 US0019803W WO0105434A3 WO 2001005434 A3 WO2001005434 A3 WO 2001005434A3 US 0019803 W US0019803 W US 0019803W WO 0105434 A3 WO0105434 A3 WO 0105434A3
Authority
WO
WIPO (PCT)
Prior art keywords
hyaluronic acid
protein
protein conjugates
present
synonymous
Prior art date
Application number
PCT/US2000/019803
Other languages
French (fr)
Other versions
WO2001005434A2 (en
Inventor
Dale Marecak
Original Assignee
Amgen Inc
Dale Marecak
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc, Dale Marecak filed Critical Amgen Inc
Priority to AU63579/00A priority Critical patent/AU6357900A/en
Publication of WO2001005434A2 publication Critical patent/WO2001005434A2/en
Publication of WO2001005434A3 publication Critical patent/WO2001005434A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof

Abstract

The present invention broadly relates to the field of protein modification and, more specifically, the attachment of low molecular weight, derivatized hyaluronic acid polymer to proteins including leptin and analogs thereof (the term 'protein' as used herein is synonymous with 'polypeptide' or 'peptide' unless otherwise indicated). The hyaluronic acid-protein conjugates of the present invention exhibit longer sustained blood levels than formulations containing protein alone, thus providing an important advantage in the therapeutic setting.
PCT/US2000/019803 1999-07-20 2000-07-20 Hyaluronic acid-protein conjugates WO2001005434A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU63579/00A AU6357900A (en) 1999-07-20 2000-07-20 Hyaluronic acid-protein conjugates, pharmaceutical compositions and related methods

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US14463999P 1999-07-20 1999-07-20
US60/144,639 1999-07-20
US61906900A 2000-07-19 2000-07-19
US09/619,069 2000-07-19

Publications (2)

Publication Number Publication Date
WO2001005434A2 WO2001005434A2 (en) 2001-01-25
WO2001005434A3 true WO2001005434A3 (en) 2001-11-15

Family

ID=26842190

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/019803 WO2001005434A2 (en) 1999-07-20 2000-07-20 Hyaluronic acid-protein conjugates

Country Status (2)

Country Link
AU (1) AU6357900A (en)
WO (1) WO2001005434A2 (en)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7173003B2 (en) 2001-10-10 2007-02-06 Neose Technologies, Inc. Granulocyte colony stimulating factor: remodeling and glycoconjugation of G-CSF
US7214660B2 (en) 2001-10-10 2007-05-08 Neose Technologies, Inc. Erythropoietin: remodeling and glycoconjugation of erythropoietin
EP2292271A3 (en) * 2001-10-10 2011-09-14 BioGeneriX AG Remodelling and glycoconjugation of an antibody
EP2298354B1 (en) * 2001-10-10 2014-03-19 ratiopharm GmbH Remodelling and glycoconjugation of interferon-beta
CA2519092C (en) 2003-03-14 2014-08-05 Neose Technologies, Inc. Branched water-soluble polymers and their conjugates
PL1615945T3 (en) 2003-04-09 2012-03-30 Ratiopharm Gmbh Glycopegylation methods and proteins/peptides produced by the methods
US8791070B2 (en) 2003-04-09 2014-07-29 Novo Nordisk A/S Glycopegylated factor IX
US9005625B2 (en) 2003-07-25 2015-04-14 Novo Nordisk A/S Antibody toxin conjugates
US8633157B2 (en) 2003-11-24 2014-01-21 Novo Nordisk A/S Glycopegylated erythropoietin
US20080305992A1 (en) 2003-11-24 2008-12-11 Neose Technologies, Inc. Glycopegylated erythropoietin
US20060040856A1 (en) 2003-12-03 2006-02-23 Neose Technologies, Inc. Glycopegylated factor IX
KR101439880B1 (en) 2004-01-08 2014-09-12 라티오팜 게엠베하 O-linked glycosylation of peptides
EP1771066A2 (en) 2004-07-13 2007-04-11 Neose Technologies, Inc. Branched peg remodeling and glycosylation of glucagon-like peptide-1 glp-1
US8143391B2 (en) 2004-09-07 2012-03-27 Chugai Seiyaku Kabushiki Kaisha Process for producing water-soluble hyaluronic acid modification
EP1799249A2 (en) 2004-09-10 2007-06-27 Neose Technologies, Inc. Glycopegylated interferon alpha
WO2006050247A2 (en) 2004-10-29 2006-05-11 Neose Technologies, Inc. Remodeling and glycopegylation of fibroblast growth factor (fgf)
CN101163506B (en) 2004-12-27 2012-09-26 巴克斯特国际公司 Polymer-von willebrand factor-conjugates
NZ556436A (en) 2005-01-10 2010-11-26 Biogenerix Ag Glycopegylated granulocyte colony stimulating factor
EP2386571B1 (en) 2005-04-08 2016-06-01 ratiopharm GmbH Compositions and methods for the preparation of protease resistant human growth hormone glycosylation mutants
JP5216580B2 (en) 2005-05-25 2013-06-19 ノヴォ ノルディスク アー／エス Glycopegylated factor IX
US20070105755A1 (en) 2005-10-26 2007-05-10 Neose Technologies, Inc. One pot desialylation and glycopegylation of therapeutic peptides
US20090048440A1 (en) 2005-11-03 2009-02-19 Neose Technologies, Inc. Nucleotide Sugar Purification Using Membranes
JP2009508852A (en) * 2006-01-23 2009-03-05 クワンジュ インスティチュート オブ サイエンス アンド テクノロジー Conjugate in which pharmacologically active substance and mucoadhesive polymer are covalently bonded, and method for transmucosal delivery of pharmacologically active substance using the same
US20070225484A1 (en) * 2006-03-25 2007-09-27 Framroze Bomi P Process for the Isolation and Stabilization of Low-Molecular Weight Aminoglycans from Waste Egg Shells
BRPI0708832A2 (en) 2006-03-31 2011-06-14 Baxter Int proteinacean construction
US7645860B2 (en) 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
ES2516694T3 (en) 2006-07-21 2014-10-31 Ratiopharm Gmbh Glycosylation of peptides through glycosylation sequences with O-binding
WO2008057683A2 (en) 2006-10-03 2008-05-15 Novo Nordisk A/S Methods for the purification of polypeptide conjugates
BRPI0809670A8 (en) 2007-04-03 2018-12-18 Biogenerix Ag methods to increase stem cell production, to increase the number of granulocytes in an individual, to prevent, treat and alleviate myelosuppression that results from cancer therapy, to treat a condition in an individual, to treat neutropenia and thrombocytopenia in a mammal, to expand hematopoietic stem cells in culture, to increase hematopoiesis in an individual, to increase the number of hematopoietic progenitor cells in an individual, and to provide stable bone marrow graft, and, oral dosage form.
CN101778859B (en) 2007-06-12 2014-03-26 诺和诺德公司 Improved process for the production of nucleotide sugars
US8207112B2 (en) 2007-08-29 2012-06-26 Biogenerix Ag Liquid formulation of G-CSF conjugate
CN103497246B (en) 2008-02-27 2016-08-10 诺沃—诺迪斯克有限公司 The Factor VlII molecule puted together
KR101309566B1 (en) * 2010-12-10 2013-09-17 포항공과대학교 산학협력단 Hyaluronic acid-protein conjugate, and preparation method thereof
DK2682409T3 (en) 2011-03-03 2017-09-11 Chugai Pharmaceutical Co Ltd Hyaluronic acid derivative modified with aminocarboxylic acid
WO2012140650A2 (en) 2011-04-12 2012-10-18 Hepacore Ltd. Conjugates of carboxy polysaccharides with fibroblast growth factors and variants thereof
CN104302670A (en) * 2012-02-07 2015-01-21 Phi生物医药股份有限公司 Method for manufacturing transdermally delivered hyaluronic acid-protein conjugate and transdermally delivered hyaluronic acid-protein conjugate manufactured using same
US11564971B2 (en) 2012-09-05 2023-01-31 Chugai Seiyaku Kabushiki Kaisha Hyaluronic acid derivative having amino acid and steryl group introduced thereinto
WO2015005459A1 (en) * 2013-07-10 2015-01-15 生化学工業株式会社 Pharmaceutical composition for respiratory administration
US11235067B2 (en) * 2017-01-27 2022-02-01 Trustees Of Tufts College Nanocomplexes of polyanion-modified proteins

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0585942A (en) * 1991-02-26 1993-04-06 Denki Kagaku Kogyo Kk Interferon-hyaluronic acid and/or its salt combined material
WO1994001483A1 (en) * 1992-07-02 1994-01-20 Collagen Corporation Biocompatible polymer conjugates
US5310881A (en) * 1990-03-30 1994-05-10 Seikagaku Corporation Glycosaminoglycan-modified protein
US5470829A (en) * 1988-11-17 1995-11-28 Prisell; Per Pharmaceutical preparation
WO1997019701A2 (en) * 1995-11-30 1997-06-05 Hamilton Civic Hospitals Research Development, Inc. Glycosaminoglycan-antithrombin iii/heparin cofactor ii conjugates
US5874417A (en) * 1993-11-30 1999-02-23 The Research Foundation Of State University Of New York Functionalized derivatives of hyaluronic acid
JP2001081103A (en) * 1999-09-13 2001-03-27 Denki Kagaku Kogyo Kk Hyaluronic acid-bound medicinal agent

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5470829A (en) * 1988-11-17 1995-11-28 Prisell; Per Pharmaceutical preparation
US5310881A (en) * 1990-03-30 1994-05-10 Seikagaku Corporation Glycosaminoglycan-modified protein
JPH0585942A (en) * 1991-02-26 1993-04-06 Denki Kagaku Kogyo Kk Interferon-hyaluronic acid and/or its salt combined material
WO1994001483A1 (en) * 1992-07-02 1994-01-20 Collagen Corporation Biocompatible polymer conjugates
US5874417A (en) * 1993-11-30 1999-02-23 The Research Foundation Of State University Of New York Functionalized derivatives of hyaluronic acid
WO1997019701A2 (en) * 1995-11-30 1997-06-05 Hamilton Civic Hospitals Research Development, Inc. Glycosaminoglycan-antithrombin iii/heparin cofactor ii conjugates
JP2001081103A (en) * 1999-09-13 2001-03-27 Denki Kagaku Kogyo Kk Hyaluronic acid-bound medicinal agent

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; IKETANI, HITOSHI ET AL: "Pharmaceuticals bonded to hyaluronic acid for liver targeting", XP002169036, retrieved from STN Database accession no. 134:242637 *
DATABASE CHEMABS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; MIMURA, SHUJI ET AL: "Antiviral and anticancer interferon-hyaluronate conjugates with improved blood half-life", XP002169037, retrieved from STN Database accession no. 119:15352 *

Also Published As

Publication number Publication date
AU6357900A (en) 2001-02-05
WO2001005434A2 (en) 2001-01-25

Similar Documents

Publication Publication Date Title
WO2001005434A3 (en) Hyaluronic acid-protein conjugates
AU2926401A (en) Novel chimeric proteins and methods for using the same
DK1223990T3 (en) Formulations of hyaluronic acid for delivery of osteogenic proteins
EP2067863A3 (en) Methods and compositions for diseases associated with amyloidosis
EP1077070A3 (en) Oral drug delivery compositions
FR13C0021I2 (en) EXENDIN-4 CONJUGATES AND THEIR MEDICAL USE
WO1997025052A3 (en) Compositions comprising pvp having an average molecular weight in the range of 3,000 to 14,000 daltons
WO2001041812A3 (en) Amphiphilic polymers and polypeptide conjugates comprising same
BR0010665A (en) Erythropoietin Pharmaceutical Compositions
WO1996024370B1 (en) Pharmaceutical non inorganic saline solutions for endonasal administration of a calcitonin
DE59407457D1 (en) BLOCKING THE ADMINISTRATION OF GermS IN HUMAN CELLS
AU1122192A (en) Anti-thrombin polypeptides
EP1281763A3 (en) Early growth response-1 (EGR-1) transcription factor
EA200400592A1 (en) Conjugates Peptide Thymosin α1 and Polymer
ATE268181T1 (en) PHARMACEUTICAL PREPARATIONS CONTAINING ALGINATES
BR0014803A (en) Peptide, pharmaceutical composition, use of one or more of the peptides, and diagnostic composition
JP2916947B2 (en) Method for stabilizing CPB-I and pharmaceutical composition
WO2003014293A3 (en) Novel polypeptide analogs and fusions and their methods of use
ES2156731A1 (en) Use of tranexamic acid for the preparation of a human fibrinogen composition
ATE521635T1 (en) PHYSIOLOGICALLY EFFECTIVE COMPLEX WITH TNF ACTIVITY
CA2086835A1 (en) Tissue plasminogen activator variants with decreased clearance
ATE417061T1 (en) SCORPION PEPTIDE AS A BLOOD PRESSURE LOWERING AGENT
DE60223232D1 (en) MUCINPEPTIDE WITH IMMUNOSIBLE PROPERTIES
BR9909271A (en) Active hemolytic proteins and genes encoding the same
JP2001172189A5 (en)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP